



SINEQUA

REAL-TIME BIG DATA SEARCH & ANALYTICS

From Search to « Cognition » ?

New York

Paris

London

Frankfurt

Evolution of Search

Human/Computer Interaction

- Facet / Taxonomy / Ontology Navigation
- Auto Suggestion (Concepts , Named Entities , ...)
- Topic Recommendation
- Analytics on results (Distribution , Correlations , ...)
- Visualization
 - Dashboards
 - Network representation & exploration
 - Geo contextualisation (Geo Mapping & Geo Search)
 - Heat Maps , Topic Maps

Evolution of Search Machine Learning

- Machine Learning Algorithms leveraging :
 - NLP , Entity Extractions & Normalizations , Word2Vec
- K Means , Expectation Maximization , Spectral Clusterization
 - Automatic Concept Clusterization
 - Content Recommendations (based on users activity)
 - Unsupervised Classification
- Logistic Regression, Deep Learning (Deep Belief Network)
 - Classification by example
 - Supervised Prediction
- Unforeseen Correlation between existing extracted entities (ex : candidates for Drug Repositioning)
- Iterative Ontology Generation

Scientific Search

Search accross internal and external sources (clinical trials, scientific publications, patents) for meaningful information regarding your products, compounds, genes, drugs...


My Search

Refine Search

OK

All Entities

- Anat (14)
- Biochem (3)
- Bioproc (15)
- Clinimes (15)
- Clinproc (17)
- Company (18)
- Drug (18)
 - Entity BMS-582664 (15)
 - Entity Brivanib (16)
 - Entity Brivanib Alaninate (17)
 - Entity Calcium Folate (2)
 - Entity Cetuximab (2)
 - Entity Docetaxel (1)
 - Entity Doxorubicin (1)
 - Entity Fluorouracil (1)
 - Entity FOLFIRI (2)
 - Entity folfox (1)
 - Entity Irinotecan Hydrochloride (2)
 - Entity Ixabepilone (1)
 - Entity Paclitaxel (1)
 - Entity Sorafenib (2)
- Ethnic (6)
- Gene (4)
- Geneont (10)
- Indication (15)
- Species (4)



18 Answers - Ordered By: Relevance

You also searched for Brivanib alaninate (and 24 synonyms) from BMS-inchikey;

All (19)

PDLIMS (1)

Matrix Vault Summaries (0)

Symyx Notebook Reports (0)


Ein Reports (0)

BMS & News (0)

Trials (18)

Studies (0)

Wikipedia (...)


 **A Phase I, Multi-arm, Dose Escalation Study of Brivanib Alaninate Combined With Several Chemotherapy Regimens in Subjects With Solid Tumors**

★★★★☆ A Phase I, Multi-arm, Dose Escalation Study of Brivanib Alaninate Combined With Several Chemotherapy Regimens in Subjects With Solid Tumors... Health Canada No To determine safety and maximum tolerated dose of brivanib alaninate when administered in combination with capecitabine, doxorubicin, ixabepilone, docetaxel and paclitaxel chemotherapy to subjects with advanced or metastatic

Bristol-Myers Squibb - 2/12/2014 12:00:00 AM - 11 Kb - /Clinical Trials/ Preview

★★★★★

Compound(s): BRIVANIB / PACLITAXEL / IXABEPILONE / BRIVANIB ALANINATE
Drug(s): DOCETAXEL / DOXORUBICIN / IXABEPILONE / BRIVANIB / PACLITAXEL / BRIVANIB ALANINATE


 **Phase I Dose Escalation Study to Determine the Safety, Pharmacokinetics and Pharmacodynamics of BMS-582664 in Patients With Advanced or Metastatic Solid Tumors**

★★★★☆ Phase I Dose Escalation Study to Determine the Safety, Pharmacokinetics and Pharmacodynamics of BMS-582664 in Patients With Advanced or Metastatic Solid Tumors... Food and Drug Administration No This is a Phase I dose escalation study to determine the safety, pharmacokinetics and pharmacodynamics of BMS-582664 in patients with advanced or metastatic solid tumors... Safety of

Bristol-Myers Squibb - 11/3/2008 12:00:00 AM - 10 Kb - /Clinical Trials/ Preview

★★★★★

Compound(s): BRIVANIB / BRIVANIB ALANINATE
Indication(s): NEOPLASM METASTASIS / KIDNEY NEOPLASMS
Drug(s): BMS-582664 / BRIVANIB / BRIVANIB ALANINATE

 **A Pharmacokinetic Study of Brivanib (BMS-582664) in Subjects With Advanced Solid Tumor Malignancies and Normal Hepatic Function or Hepatocellular Carcinoma With Impaired Hepatic Function**

★★★★☆ A Pharmacokinetic Study of Brivanib (BMS-582664) in Subjects With Advanced Solid Tumor Malignancies and Normal Hepatic Function or Hepatocellular Carcinoma With Impaired Hepatic Function... Food and Drug Administration No The primary purpose of this protocol is to determine the effect of BMS-582664 on patients with hepatocellular carcinoma with varying levels of hepatic impairment

Bristol-Myers Squibb - 5/2/2011 12:00:00 AM - 6 Kb - /Clinical Trials/ Preview

★★★★★

Compound(s): BRIVANIB / BRIVANIB ALANINATE

Structure Search

Find all documents linked to a chemical structure or sub-structure. Capability to search from structure schema, .mol files, InChI-key, internal ID...

56 59 0 0 1 0 0 0 0 0999 V2000
3.6202 1.4382 -1.2945 F 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
2.2055 0.1607 0.6741 O 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
-3.2418 -0.6800 0.5016 O 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
-5.8758 0.3700 -0.0386 O 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
-8.0468 -0.6000 0.0000 O 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
-0.2708 -2.6000 0.0000 O 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
0.6163 -2.5000 0.0000 O 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
2.4176 -1.6000 0.0000 O 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
7.6859 0.5000 0.0000 O 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
-8.8296 2.6000 0.0000 O 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
0.2530 -1.6000 0.0000 O 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
1.6529 -0.8000 0.0000 O 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
-0.8035 -0.3000 0.0000 O 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0

Draw a structure

Matrix Vault Summaries (0)

vanib alaninate (and 24 synonyms) from BMS-inhibitor

A Phase I, Multi-arm, Dose Escalation Study of
A Phase I, Multi-arm, Dose Escalation Study of Brivanib Al with capecitabine, doxorubicin, ixabepilone, docetaxel and
Bristol-Myers Squibb - 2/12/2014 12:00:00 AM - 11 Kb - /Clinical
★★★★★
Compound(s): BRIVANIB / PACLITAXEL / IXABEPILONE / BRIVANIB
Drug(s): DOXETAXEL / DOXORUBICIN / IXABEPILONE / BRIVANIB

Phase I Dose Escalation Study to Determine th
Phase I Dose Escalation Study to Determine the Safety, PK pharmacokinetics and pharmacodynamics of BMS-582664
Bristol-Myers Squibb - 11/3/2008 12:00:00 AM - 10 Kb - /Clinical
★★★★★
Compound(s): BRIVANIB / BRIVANIB ALANINATE
Indication(s): NEOPLASM METASTASIS / KIDNEY NEOPLASMS
Drug(s): BMS-582664 / BRIVANIB / BRIVANIB ALANINATE

11154925
649735-63-7
A20636
BMS 582664
BMS582664
BMS-582664
BMS-582664, 649735-63-7
Brivanib alaninate
Brivanib alaninate - BMS-582664
Brivanib alaninate (BMS-582664)
Brivanib alaninate (JAN/USAN/INN)
Brivanib alaninate.BMS-582664
Brivanib alaninate:649735-63-7/BMS 582664/BMS582664
Brivanib alaninate-Supplied by Selleck Chemicals
CC1=CC2=C(N1)C=CC(=C2F)OC3=NC=NN4C3=C(C(=C4)OC[C@@H](C)OC(=O)[C@H](C)N)C
CC1=CC2=C(N1)C=CC(=C2F)OC3=NC=NN4C3=C(C(=C4)OC[C@@H](C)OC(=O)[C@H](C)N)C
cc-420
CS-0159
FT-0663602
HY-10336
InChI=1S/C22H24FN5O4/c11-17-15-16(27-11)5-6-17(19(15)23)32-21-20-13(3)18(8-28(20)26-10-25-21)30-9-12(2)31-22(29)14(4)24/h5-8,10,12,14,27H,9,24H2,1-4H3/t12-14-/m1/s1
LTEJRLHKIYCEOX-OCCSQVGLSA-N
RLD4475
SureCN483382

COMPLIANCE (ALL NEWS)(5 DAYS)

Close

Observation

Closure

Training

banned

import ban

critical

FAR

4

0

0

7

1

0

1

1

15

13

8

8

6

6

5

5

▲ 275%

NEW

NEW

▲ 14%

▲ 500%

NEW

▲ 400%

▲ 400%

GROWTH

▲ 0%

▲ 300%

▲ 200%

NEW

▲ 200%

NEW

▲ 100%

U.S. Department of Health & Human Services

FDA

U.S. Food and Drug Administration

Protecting and Promoting Your Health

Home

Food

Drugs

Medical Devices

Radiation-Emitting Products

Vaccines, Blood & Biologics

Animal & Veterinary

Cosmetics

Tobacco Products

3/29/10

Warning Letter


Public Health Service

Food and Drug Administration

Silver Spring MD 20993

VIA FEDERAL EXPRESS MAIL

WL: 320 - 10 - 003



aboriginal medicine Acceptable Quality Level active pharmaceutical ingredients airflow pattern studies alleging malice appropriate action **banned** banned drugs blood pressure Canada Imm
Canadian patent Canadian patent cleaning procedures community clinic Computational Biology control strategy cross-undertaking data integrity Dear Health Care Professional defective
defective medications dissolution specification drug ban drug giant Drug makers empty capsules **Equipment** equipment malfunction EXPIRY fill protocol Foreign material Generic Drug
Global Medical Affairs Grand Round **health minister** heart problems import ban import ban inaccurate reporting inadequate preventive maintenance Information Update Labeling Suit lack of raw
data supporting largest suppliers leaking desiccant Lighthouse Legal Mailing address material properties Out of Specification Out of Trend **Parkinson's drug** process validation Pro-Doc product
quality quality issue reassigning batch **recalled recalling** Recalling Firm recalls Release releasing batches reliability repackaging reporting rates respective manufacturers risk
assessment self-harm shelf life sterility failure sterility test Supreme Court Supreme Court Canada sweeping action Toronto M9L Toronto Star translational research
unexpected adverse reactions unidirectional airflow unidirectional airflow pattern studies


CGMP VIOLATIONS

1. Your firm's quality control unit failed to follow the responsibilities and procedures applicable to release

For example, (b)(4), an Active Pharmaceutical Ingredient (API), batch # [REDACTED], was found to be contaminated with (b)(4) materials. You rejected part of this lot. However, you used a portion of this contaminated API to manufacture Celebrex-MC Film Coated Tablets, 10 mg tablets, NDC [REDACTED], and [REDACTED].

Competitive intelligence

Collect precious information on your main competitors (products, litigations, clinical trials, patents, nominations, ...).
Provide dashboards and automate newsletters to right people within your company.



New Insights from Content

Extract relations between entities (drugs, diseases, people, after-effects) to discover new links and relations. Thanks to unique graphic visualization, work on drug repositioning, explore all your compounds to check preceding alerts and usages. This is mainly used for drug repositioning.



R&D Intelligence

Number of Connections



Back to graph

Sentences

Active areas of research in EGFR-mutant and ALK-translocated NSCLC include identification of mechanisms of resistance and overcoming them	External Read document
Anaplastic lymphoma kinase gene rearrangements in patients with advanced-stage non-small-cell lung cancer Few articles have been published on the imaging findings of anaplastic lymphoma kinase (ALK)-positive class="entityone">non-small-cell lung cancer (NSCLC) To investigate the radiological findings of ALK-positive class="entityone">NSCLC in the advanced stage, CT scans were examined Of the 36 patients with ALK-rearranged class="entityone">NSCLC, a mass and a nodule were identified in 17 (47.2%) and 16 (44.4%), respectively, indicating that more than 40% had a small-sized tumor.	External Read document
ROS1-positive NSCLCs arise in young never-smokers with adenocarcinoma that are similar to those observed in patients with ALK-rearranged class="entityone">NSCLC	External Read document
ROS1 proto-oncogene translocations define a new molecular subgroup in non-small cell lung cancers (NSCLC) and are associated with a response to the MET/ALK inhibitor, crizotinib These rearrangements are described in 0.9-1.7% NSCLC, in wild-type EGFR, KRAS and ALK ("triple negative") lung adenocarcinomas	External Read document
Pemetrexed-based chemotherapy in patients with advanced, ALK-positive class="entityone">non-small cell lung cancer	External

R&D Pulse : Alerting & New Trends

Welcome Christian (Admin)

Temp Locked Only R&D Department R&D Search R&D Labs Help

R&D Pulse

diabetes



Search

Advanced Search

My Search

diabetes

Refine Search


OK

Sources

- ☐ External (4,508)
 - ☐ Clinical trials (1,705)
 - ☐ Grants (23)
 - ☐ News (791)
 - ☐ Patents (725)
 - ☐ Publications (1,264)
- ☐ Internal (270)
 - ☐ FileShare (153)
 - ☐ PKT (63)
 - ☐ SharePoint (54)

Click Stars To Save Favourites

My Favourites 0



4,778 Answers - Ordered By: Date

Create an email alert for *diabetes*

You also searched for *Diabetes Mellitus* (and 9 synonyms) from AZ Disease ;

Results

Pulse Map

Effects of sodium restriction and hydrochlorothiazide

Efficacy and safety of empagliflozin

Efficacy and safety of empagliflozin

Efficacy and safety of empagliflozin added to existing antidiabetes treatment in patients with type 2 diabetes and chronic kidney disease: a randomised, double-blind, placebo-controlled trial

Efficacy And Safety Of Empagliflozin Added To Existing Antidiabetes Treatment In Patients With Type 2 Diabetes And Chronic Kidney Disease: A Randomised, Double-blind, Placebo-controlled Trial Efficacy And Safety Of Empagliflozin Added To Existing Antidiabetes Treatment In Patients With Type 2 Diabetes And Chronic Kidney Disease: A Randomised, Double-blind, Placebo-controlled Trial Background Diabetes Is A Leading Cause Of Chronic Kidney Disease (Ckd) Worldwide. Optimum Glycaemic Control In Pa...

Mon, 12 May 2014 17:00:02 GMT

/External/news.daily/

Effect of insulin analogues on risk of...

Midatech forms prestigious Scientific Advisory Board

Brillinta DT TPP key characteristics slide...

BS000738-05_Study Protocol_LPS_Timecourse

Nexium, Axanum and GI Established Brands Global...

Pharmaceutical formulations containing an SGLT2 inhibitor

Method and device for utilizing analyte levels...

Customer error screen capture

CDxT Agenda Minutes 15 Feb 12

Est CV Brands GPT Minutes 2011-10-26

Est CV Brands GPT Minutes 2011-10-26

Personal assessment including familial risk analysis for...

Subcutaneous insulin analogues as expected insulin...

Insulin pump with blood glucose modules

CDxT CVGI Impact Summariser 2012May25

18042

Modified extendins and uses thereof

Optimizing the performance of the...

UPLC Liquid Chromatograph

Healthier White Adipose by Recruitment of Beige/

Treating Sleep Apnea in Type

The role of TCF7L2 in

Expert Search & KOL's

Find matter experts implicitly deduced from all the internal & external R&D content. Build and visualize experts (and KOL's) and Knowledge networks/connections thanks to visualization and analytics capabilities.

